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Chapter 31
OVERVIEW OF PERFLUOROOCTANOIC ACID
State of the Science
Brooke Moore, E.I.T.
ENSR Corporation

Abstract:

The US Environmental Protection Agency (EPA) has been reviewing data and developing a draft risk
assessment for Perfluorooctanoic Acid (PFOA). PFOA is a synthetic chemical, sometimes referred to as
“C8”, used by chemical companies and manufacturers to make non-stick cookware, water repellant coatings
for all-weather clothing and fabrics, food packing, gaskets, O-rings, and hoses. It is chiefly used in producing
fluoropolymers which are employed in almost all commercial industry segments including aerospace,
automotive, building/construction, chemical processing, electrical and electronics, semiconductor, and textile
industries. The durability of PFOA due to its specific chemical structure prevents breakdown in the
environment which leads to widespread persistence in the environment. It is this persistence which prompted
the EPA to conduct a further evaluation of PFOA and its potential to adversely affect human health.
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1.

INTRODUCTION

Perfluorooctanoic Acid (PFOA) is a synthetic chemical discovered in the mid-20th century by a
well established chemical company. The term PFOA is used to describe not only the carboxylic acid
C8HF15O2, but also a family of perfluorinated chemicals including perfluorooctanoic salts. PFOA is
also sometimes referred to as “C8” which the amount of carbon chains found the molecule.
Widespread interest in the health impacts of PFOA has been sparked due to recent media attention to
this chemical and EPA scrutiny of PFOA. This paper was written to inform the reader about PFOA’s
chemical composition, historical use and production, known toxicity, and actions taken by the EPA
and state agencies regarding regulations.

2.

SOURCES

PFOA is chiefly used by chemical companies and manufacturers to make fluoropolymers, which
are utilized in the manufacture of non-stick cookware and breathable, stain resistant, all-weather
clothing (US EPA, 2006). Given fluoropolymers’ unique nature to be both hydrophobic and
lipophoic, products containing fluoropolymers are used in almost every major commercial industry
from automotive to food packaging. While PFOA is used the production of these compounds,
finished fluoropolymer products are not intended to contain PFOA. According to the Society of the
Plastics Industry, Inc. (SPI), PFOA is largely removed, recycled, or destroyed during the final stages
of fluoropolymer production by high-temperature processing when fluoropolymers are made into
finished products (Society of Plastics Industry, 2005). Although, PFOA may not be part of an endproduct; those fluoropolymers eventually thermally or biologically decompose to form daughter
products including PFOA.
Between 1992 and 2002, the only major US manufacture of PFOA at the time averaged
approximately 250,000 pounds per year in production. Less than 600 metric tons per year of PFOA
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and its salts were manufactured in the US or imported in recent years (USEPA, 2002). Ninety-seven
percent of the amount produced was distributed to industrial clientele or used in the companies’ own
fluoropolymer production. The remaining portion was used in medical film coating applications and
circuit boards and precision bearings (Wendling, 2003).

3.

EMISSIONS

PFOA emissions into air and surface water near plants have been heavily scrutinized by the EPA,
causing companies to pay specific attention to point source emissions. According to company
documents of the only current US manufacture of PFOA, approximately 85% of the PFOA produced
by their facilities in 2003 was either recovered or destroyed. By 2004, the percentage recovered or
destroyed had increased to 98% (DuPont, 2005).
In the late 1990’s, EPA received information indicating that perfluorooctyl sulfonates (PFOS), a
perfluorinated chemical similar in nature to PFOA, were widespread in the blood of the general
population, and presented concerns for its persistence in the environment, potential for
bioaccumulation, and general toxicity. Following discussions between the EPA and PFOS’s
manufacturer, the company terminated production of these chemicals. Findings on PFOS led the EPA
to review similar compounds, including PFOA, starting in 2000, to determine whether they might
present similar concerns (US EPA, 2006).
Given the EPA’s scrutiny of PFOA, the only US major manufacturer at that time halted production
in 2002 in search of alternative chemicals. Following the loss of their supplier, a major user of PFOA
began producing the chemical, and has since been the only producer of PFOA in the US.

4.

PFOA PROPERTIES

Most of the data and experiments associated with PFOA have been in aqueous solutions. Given
the carboxylic structure of the atom, it is speculated that the most viable form in the environment
would be the perfluorooctanoic ion. The high solubility (3400-9500 mg/l) and low vapor pressure
(0.5-10 mmHg) help to bolster this claim. However, scientists agree that additional soil, sediment and
air tests are need for confirmation (Santoro, 2003).
Due to the chemical structure of the molecule, PFOA is extremely stable in the environment.
Multiple studies by private companies do not exhibit significant biodegradability of PFOA itself under
normal environmental conditions (USEPA, 2002).

5.

EXPOSURE PATHWAYS

The EPA was prompted to investigate PFOA due to concentrations found in a sampling of blood
from blood banks. One study on blood serum samples collected in 2001 and 2002 showed
perfluorinated chemicals (PFCs), including PFOA, are found in both genders and in similar
concentrations for varying age groups. This suggests that PFOA does not bioaccumulate in the body.
In addition, concentrations in the US are similar to those found in Japan, Canada, and in Europe.
PFCs distribute predominately in the liver and blood plasma and their persistence is related more to a
long half-life rather than bioaccumulation in fatty tissues, as with other chemicals (Calafat, 2006).
Exposure pathways for PFOA outside of the manufacturing facilities are not completely
understood. Some scientists speculate that PFOA and related chemicals can be ingested, inhaled or
possibly adsorbed through dermal contact (Begley).
In January 2005, the EPA completed its Draft Human Health Risk Assessment (HHRA) for PFOA.
In the Draft HHRA, the EPA used a Margin of Exposure (MOE) to evaluate non-cancer endpoints.
Significant findings included the following:
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1. Epidemiological studies of mostly male workers in PFOA production facilities. –result:
first study indicated a statistically significant association between prostate cancer mortality
and employment duration, not confirmed by the second update study.
2. Serum cholesterol and triglyceride levels in the same workers were positively linked to
PFOA exposures, (consistent with effects observed in a laboratory rats study) (SAB,
2005).
3. PFOA primarily distributes to the liver, serum, and kidneys, is not metabolized, with
enterohepatic circulation.
4. Ammonium salt of PFOA does not appear to be a mutagenic.
5. Children, ages 2-12 years old, included in the blood serum study (n=598) had PFOA levels
of 5.6 ppb, with some levels as high as 56.3 ppb. (SAB 2005).
6. Another study of PFOA half-life in humans indicated a half life of approximately 4.4
years.
7. A 13-week study performed on Rhesus monkeys: >30 mg/kg per day fatal, but clinical
signs of toxicity at 3 mg/kg/day. Repeat doses showed primary target organ = liver; but
symptoms from exposure to 300 parts per million (ppm) for 2 years included an increase
in liver weight, hepatocellular hypertrophy, hematological effect, and testicular masses
(SAB 2005). Studies reviewed by the EPA showed possible links between PFOA and
developmental, liver, kidney, and reproductive issues in rats. Routes of exposure in the
rodent subjects were observed through inhalation, ingestion, and dermal adsorption
pathways.
Given the information reviewed, the EPA recommended PFOA be given a descriptor of suggested
carcinogen (US EPA, 2006). The Draft HHRA was reviewed by the Scientific Advisory Board
(SAB), which is customary for potential regulatory documents. Based on its review of the Draft
HHRA, the SAB concluded that the current documentation more closely describes a likely carcinogen
rather than a suggested carcinogen, suggesting the data shows PFOA as a “multi-site, multi-gender”
carcinogen (SAB 2005). The SAB requested additional studies be conducted to provide additional
information regarding the toxicity and potential carcinogenicity of PFOA. Additional studies on
PFOA toxicology and pharmokenetics are being conducted by the EPA, Center for Disease Control
(CDC), and other government agencies and private companies.
As of the date of this paper, the EPA has not developed any cancer-based toxicity values. Nor has
the EPA published screening levels for PFOA or related compounds for various media (soil,
groundwater, etc.). Due to the presence of PFOA manufacturing and/or primary utilization facilities
within their jurisdiction, several states have established screening levels. West Virginia Department
of Environmental Protection (WVDEP) completed a C8 Assessment and Toxicity Team Report and
established an inhalation and ingestion reference dose based on available toxicity data (CATT 2002).
From there, WVDEP established screening levels for air (1 ug/m3), groundwater (150 ug/l), and soils
(240 mg/kg). One other state environmental agency, the New Jersey Department of Environmental
Protection (NJDEP), has established a generic screening level (NJDEP = 5 ug/l for ground/surface
water) (GIST, 2003). However, the EPA has not endorsed these screening levels. Most of the
observed concentrations in surface water and groundwater have been in the parts per trillion.

6.

CURRENT STATUS

The EPA has signed Enforceable Consent Agreements (ECAs) with leading manufactures and
users of PFOA to monitor emissions and media concentrations surrounding plants. In addition, the
EPA, the only US manufacturer, the former US manufacturer, and six other leading users of PFOA
have signed a Global Stewardship Program to reduce PFOA emissions by 95% by 2010, and eliminate
the use of PFOA by 2015 (Johnson, 2006).
While questions still remain regarding the full toxicity, routes of exposure, and potential health
effects for humans, the EPA is currently taking steps to remove PFOA from the manufacturing
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process. In the upcoming year, additional information on the potential health effects associated with
exposure to PFOA and its related compounds should be released by the EPA, the CDC, and private
companies.
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